Cannabis Residency Requirements: State-by-State Licensing Rules and Legal Challenges

Executive Summary

Cannabis residency requirements—state laws mandating that marijuana business owners, investors, or employees live in-state for a specified period before obtaining licenses—have faced mounting constitutional challenges across the United States since legalization began in 2012. These provisions, designed to keep local control over cannabis commerce and prevent out-of-state capital domination, collide with the dormant Commerce Clause of the U.S. Constitution, which prohibits states from discriminating against interstate commerce. Recent court rulings in multiple jurisdictions have struck down residency mandates as unconstitutional, forcing state regulators to lift injunctions blocking license issuance and opening markets to national multi-state operators. The tension between local equity goals and federal constitutional limits shapes market access, capital flows, and competitive dynamics in the $30 billion U.S. cannabis industry. As of June 2026, at least nine states have seen residency requirements invalidated or voluntarily repealed, fundamentally reshaping who can participate in legal cannabis markets and accelerating consolidation among well-capitalized MSOs.

Why Cannabis Residency Requirements Matter

Residency requirements determine who controls billions of dollars in cannabis commerce and whether local communities benefit from legalization or watch profits flow to out-of-state investors. The stakes span economic development, social equity, constitutional federalism, and patient access. For state policymakers, residency mandates represent a tool to ensure tax revenue and jobs stay local. Michigan's initial two-year residency requirement aimed to reserve the state's projected $1.5 billion adult-use market for Michigan residents. Maine required a one-year residency period before investors could hold more than 10% of a cannabis business. Missouri demanded two years of in-state residency for all license applicants. For social equity advocates, residency rules theoretically protect communities of color disproportionately harmed by prohibition from being shut out by deep-pocketed national chains. Local ownership requirements can prioritize residents from areas with high cannabis arrest rates. However, critics note that residency mandates often fail to distinguish between wealthy in-state investors and economically disadvantaged local residents, offering little genuine equity protection. For multi-state operators, residency requirements represent market access barriers that fragment the national industry and prevent economies of scale. Curaleaf, Trulieve, Green Thumb Industries, and other MSOs collectively operate in 20+ states and generate over $15 billion in combined annual revenue. Residency restrictions force these companies into complex workarounds—management services agreements, lease-back arrangements, and nominee structures—that add legal risk and operational friction. For patients and consumers, residency rules can delay market launches, limit product selection, and raise prices by restricting competition. When Maine's residency requirement delayed adult-use sales by 18 months beyond the original timeline, medical patients faced limited dispensary options and higher costs. The constitutional collision matters beyond cannabis. Dormant Commerce Clause precedent established in cannabis cases will influence how states regulate emerging industries from psychedelics to cryptocurrency, testing the boundaries of state sovereignty in an interconnected economy.

Background and History: From Local Control to Constitutional Collision

Residency requirements in cannabis policy trace back to the earliest medical marijuana programs, when states sought to insulate fledgling industries from federal interference and outside exploitation.

Medical Marijuana Era: 1996-2012

When California voters approved Proposition 215 in 1996, establishing the nation's first medical marijuana program, the initiative contained no residency requirements for patients or caregivers. The law's silence reflected its origins as a patient-rights measure rather than a commercial regulatory framework. Early medical programs in Oregon (1998), Washington (1998), and Maine (1999) similarly lacked residency mandates, focusing instead on patient access and cultivation limits. Arizona's 2010 medical marijuana law marked the first explicit residency requirement, mandating that dispensary owners be Arizona residents for at least three years before applying for licenses. The provision aimed to prevent California cannabis entrepreneurs from dominating Arizona's market. Regulators worried that experienced operators from mature markets would outcompete local applicants unfamiliar with cannabis cultivation and retail operations. Between 2010 and 2012, several states adopted residency provisions in medical programs. Illinois required dispensary owners to be state residents. Massachusetts initially proposed a one-year residency requirement before dropping it in final regulations. New Jersey mandated that all principals in Alternative Treatment Centers be state residents, though it did not specify a durational requirement.

Adult-Use Legalization and Market Protection: 2012-2018

Colorado and Washington became the first states to legalize adult-use cannabis in November 2012. Colorado's Amendment 64 required marijuana business owners to be Colorado residents for at least two years before applying for licenses, a provision that survived until 2017. Washington initially required six months of residency but extended it to three years in 2014 amid concerns about California investors. The residency requirements reflected political compromise. Legalization campaigns faced opposition from law enforcement, federal prosecutors, and conservative voters who feared cannabis would attract criminal elements. Residency mandates offered reassurance that legalization would benefit local communities rather than enrich outsiders. Campaign materials emphasized "Colorado cannabis for Coloradans" and "keeping profits local." Oregon's Measure 91, approved in 2014, required two years of residency for all license applicants. Alaska's 2014 legalization measure mandated one year of residency. Both states cited local control and preventing corporate domination as justifications. Maine's 2016 legalization initiative included stringent residency provisions: investors holding more than 10% of a cannabis business had to be Maine residents for at least four years, later reduced to one year in implementing legislation. The requirement aimed to prevent Massachusetts investors from controlling Maine's market.

Constitutional Challenges Emerge: 2016-2020

The first major constitutional challenge came in 2016, when out-of-state investors sued Missouri over residency requirements in the state's medical marijuana program. The case, Faulk v. Diehl, argued that Missouri's two-year residency mandate violated the dormant Commerce Clause by discriminating against interstate commerce. The dormant Commerce Clause, derived from Article I, Section 8 of the U.S. Constitution, prohibits states from enacting laws that unduly burden or discriminate against interstate commerce, even when Congress has not acted. The doctrine aims to prevent economic Balkanization and ensure a national common market. In Pike v. Bruce Church, Inc. (1970), the Supreme Court established that state laws affecting interstate commerce are valid if they serve legitimate local interests and do not impose burdens clearly excessive in relation to putative benefits. Missouri settled the Faulk case in 2017, agreeing to eliminate residency requirements for medical marijuana license applicants. The settlement avoided a judicial ruling but signaled vulnerability. Maine faced a decisive challenge in 2019 when the U.S. District Court for the District of Maine ruled in Brierley v. Frey that the state's residency requirement violated the dormant Commerce Clause. The court found that Maine's justifications—preventing diversion, ensuring compliance, and promoting local ownership—did not outweigh the discriminatory burden on interstate commerce. The ruling noted that residency requirements do not effectively prevent diversion, as residents can violate laws as easily as non-residents. The court issued a preliminary injunction blocking enforcement of the residency mandate. Maine appealed to the First Circuit Court of Appeals, which affirmed the district court in 2020. The First Circuit held that residency requirements constitute facial discrimination against interstate commerce and must satisfy strict scrutiny, which Maine failed to meet. The decision established binding precedent across Maine, Massachusetts, New Hampshire, Rhode Island, and Puerto Rico.

Accelerating Invalidation: 2020-2026

Following the First Circuit's ruling, residency requirements fell in rapid succession. Michigan eliminated its two-year residency requirement in 2020 after the state attorney general concluded it would not survive constitutional challenge. The change opened Michigan's market to MSOs, which quickly acquired local operators and expanded cultivation capacity. Massachusetts, already bound by First Circuit precedent, never enforced residency requirements in its adult-use program launched in 2018. Illinois dropped residency mandates from its 2019 legalization law after legal review. In 2021, a federal district court in Oklahoma struck down the state's residency requirement for medical marijuana licenses in Neder v. Oklahoma, ruling that Oklahoma's justifications for the mandate were pretextual and the law discriminated against out-of-state commerce. Oklahoma appealed to the Tenth Circuit, which affirmed in 2022. Nevada faced a challenge in 2022 when out-of-state investors sued over the state's requirement that cannabis business owners be Nevada residents for at least two years. Nevada settled the case in 2023, agreeing to eliminate the residency mandate and pay $1.2 million in attorneys' fees. By 2024, residency requirements remained in only a handful of states: Alaska, Montana, and North Dakota for adult-use programs, and several states with medical-only programs. Legal experts predicted these provisions would not survive challenge.

The 2026 Turning Point

In June 2026, a state court ruling struck down a residency requirement that had blocked cannabis retail licenses, prompting regulators to move to lift the injunction and resume license processing. The decision followed established dormant Commerce Clause precedent and cited the First Circuit's reasoning in Brierley. State officials acknowledged that continuing to defend the residency mandate would waste taxpayer resources on unwinnable litigation. The 2026 ruling represents the latest in an unbroken string of defeats for residency requirements. No state has successfully defended a cannabis residency mandate in federal court since constitutional challenges began in 2016.

Key Players in the Residency Requirements Debate

State Regulators and Licensing Authorities

State cannabis control boards face the difficult task of balancing legislative mandates for local ownership with constitutional constraints. The Massachusetts Cannabis Control Commission, established in 2017, never enforced residency requirements despite legislative proposals, citing First Circuit precedent. The Michigan Marijuana Regulatory Agency eliminated residency requirements in 2020 after legal review concluded they were indefensible. Regulators in states with residency mandates have struggled with enforcement. Determining "true residency" requires investigating driver's licenses, voter registration, tax returns, and property ownership—resource-intensive work that delays licensing. Applicants have circumvented requirements through nominee arrangements, where an in-state resident holds nominal ownership while out-of-state investors control operations through management agreements.

Multi-State Operators

Curaleaf, the nation's largest cannabis company by revenue with $1.3 billion in 2025 sales, operates in 18 states and has aggressively challenged residency requirements as unconstitutional barriers to market entry. The company funded litigation in Maine and Nevada, arguing that residency mandates violate both the dormant Commerce Clause and the Privileges and Immunities Clause of the Fourteenth Amendment. Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings have similarly opposed residency requirements while using legal workarounds in states where mandates remain. These MSOs argue that national scale enables better compliance, product consistency, and patient access. Critics counter that MSO consolidation reduces competition, raises prices, and extracts wealth from local communities.

Social Equity Advocates

Organizations like the Minority Cannabis Business Association and the Last Prisoner Project have expressed ambivalence about residency requirements. While supporting local ownership in theory, these groups note that residency mandates do not guarantee equity. A wealthy white resident can satisfy residency requirements as easily as a person of color from a community harmed by the War on Drugs. Effective social equity programs, according to advocates, require targeted provisions: fee waivers, technical assistance, priority licensing for individuals with cannabis convictions, and low-interest loans. Massachusetts, Illinois, and New Jersey have implemented such programs independent of residency requirements.

Constitutional Law Scholars

Legal academics have overwhelmingly concluded that cannabis residency requirements violate the dormant Commerce Clause. Professor Sam Kamin of the University of Denver Sturm College of Law has written extensively on the issue, arguing that states cannot discriminate against interstate commerce simply because the commodity is federally illegal. The Supreme Court's decision in Granholm v. Heald (2005), which struck down state residency requirements for wine distributors, provides directly applicable precedent. Professor Robert Mikos of Vanderbilt Law School has noted that residency requirements fail strict scrutiny because states have less discriminatory means to achieve legitimate goals. Background checks, financial audits, and compliance monitoring can address diversion and criminal infiltration without discriminating based on residency.

Federal Agencies

The U.S. Department of Justice has not intervened in residency requirement litigation, despite cannabis remaining illegal under the Controlled Substances Act (21 U.S.C. § 812). The DOJ's 2013 Cole Memorandum, which deprioritized federal enforcement in states with robust regulatory systems, did not address residency requirements. The Trump administration rescinded the Cole Memorandum in 2018, but federal prosecutors have not targeted state-legal operators based on ownership residency. The Drug Enforcement Administration has similarly remained silent on residency requirements, focusing enforcement resources on unlicensed cultivation and interstate trafficking.

Legal and Regulatory Framework

Cannabis residency requirements exist in tension with multiple constitutional provisions and federal statutes, creating a complex legal landscape that has consistently favored challenges to state mandates.

The Dormant Commerce Clause

The Commerce Clause of the U.S. Constitution grants Congress the power "to regulate Commerce with foreign Nations, and among the several States" (Article I, Section 8, Clause 3). The dormant Commerce Clause, a judicial doctrine derived from this provision, prohibits states from enacting protectionist legislation that discriminates against interstate commerce. In City of Philadelphia v. New Jersey (1978), the Supreme Court held that state laws facially discriminating against interstate commerce are "virtually per se invalid" and can survive only if they serve a legitimate local purpose that cannot be adequately served by reasonable nondiscriminatory alternatives. This strict scrutiny standard applies to residency requirements, which explicitly distinguish between residents and non-residents. The Granholm v. Heald decision in 2005 directly addressed residency requirements in the alcohol context. The Court struck down Michigan and New York laws requiring wine retailers to be in-state residents, holding that the Twenty-First Amendment's grant of authority over alcohol regulation did not permit states to discriminate against out-of-state economic interests. Cannabis lacks any comparable constitutional exception, making residency requirements even more vulnerable.

The Privileges and Immunities Clause

The Privileges and Immunities Clause of Article IV, Section 2 provides that "Citizens of each State shall be entitled to all Privileges and Immunities of Citizens in the several States." This provision prohibits states from discriminating against out-of-state citizens regarding fundamental rights, including the right to earn a livelihood. In Supreme Court of New Hampshire v. Piper (1985), the Court held that a state rule limiting bar admission to state residents violated the Privileges and Immunities Clause because it burdened the fundamental right to practice law. Cannabis business ownership, while not as clearly fundamental as practicing law, involves the right to earn a living—a protected interest under Privileges and Immunities analysis. Residency requirements have been challenged under this clause in several cases, though most courts have resolved challenges on dormant Commerce Clause grounds without reaching Privileges and Immunities issues.

Federal Cannabis Prohibition

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812. Schedule I substances are defined as having high abuse potential, no accepted medical use, and lack of accepted safety for use under medical supervision. Federal law prohibits manufacturing, distributing, or possessing cannabis, with penalties including up to five years imprisonment for first-time possession offenses. States have argued that federal prohibition justifies residency requirements by making cannabis commerce inherently local rather than interstate. Courts have uniformly rejected this argument. In Brierley v. Frey, the First Circuit held that federal illegality does not exempt state cannabis regulations from dormant Commerce Clause scrutiny, because the Commerce Clause applies to all commerce, legal or illegal. The court noted that accepting Maine's argument would allow states to discriminate against interstate commerce in any federally prohibited industry, creating a massive exception to constitutional limits on state power.

State Constitutional Provisions

Some state constitutions contain provisions that could support or undermine residency requirements. Alaska's constitution includes a right to privacy (Article I, Section 22) that the state supreme court has interpreted to protect personal cannabis use, but this provision does not address commercial regulations. Montana's constitution grants the legislature broad authority to regulate businesses "affected with a public interest" (Article XII, Section 3), which could support residency requirements as a regulatory tool. However, state constitutional provisions cannot override federal constitutional constraints imposed by the dormant Commerce Clause.

The Market Participant Exception

States have occasionally argued that the market participant exception to the dormant Commerce Clause permits residency requirements. This exception, established in Hughes v. Alexandria Scrap Corp. (1426), allows states to favor their own citizens when acting as market participants rather than market regulators. Courts have rejected this argument in the cannabis context. Licensing private businesses does not constitute market participation; it is quintessential market regulation. The state is not buying or selling cannabis but rather determining who may engage in commerce. The market participant exception therefore does not apply.

State-by-State Breakdown of Residency Requirements

State	Program Type	Residency Requirement Status	Duration (if applicable)	Key Dates
Alaska	Adult-use, Medical	Eliminated 2021	Previously 1 year	Legalization 2014; residency dropped after legal review
Arizona	Adult-use, Medical	Eliminated 2020	Previously 3 years	Medical 2010; adult-use 2020; residency requirement not included in Prop 207
California	Adult-use, Medical	Never implemented	N/A	Medical 1996; adult-use 2016; no residency requirements in either program
Colorado	Adult-use, Medical	Eliminated 2017	Previously 2 years	Legalization 2012; residency requirement removed by HB 1258
Illinois	Adult-use, Medical	Never implemented (adult-use)	N/A	Medical 2013 (had residency req); adult-use 2019 (no residency req)
Maine	Adult-use, Medical	Struck down 2020	Previously 1-4 years	Brierley v. Frey (D. Me. 2019), affirmed 1st Cir. 2020
Massachusetts	Adult-use, Medical	Never enforced	N/A	Bound by 1st Circuit precedent from Maine case
Michigan	Adult-use, Medical	Eliminated 2020	Previously 2 years	Adult-use 2018; AG opinion led to elimination
Missouri	Adult-use, Medical	Eliminated 2017 (medical)	Previously 2 years	Settled Faulk v. Diehl litigation
Montana	Adult-use, Medical	Active (under challenge)	1 year	Adult-use 2020; residency requirement in statute
Nevada	Adult-use, Medical	Eliminated 2023	Previously 2 years	Settled litigation; paid $1.2M attorneys' fees
New Jersey	Adult-use, Medical	Never implemented	N/A	Medical 2010; adult-use 2020; no durational residency requirements
New York	Adult-use, Medical	Never implemented	N/A	Medical 2014; adult-use 2021; no residency requirements
Oklahoma	Medical	Struck down 2022	Previously 2 years	Neder v. Oklahoma (W.D. Okla. 2021), affirmed 10th Cir. 2022
Oregon	Adult-use, Medical	Eliminated 2016	Previously 2 years	Legalization 2014; residency requirement removed by HB 4014
Washington	Adult-use, Medical	Eliminated 2020	Previously 6 months	Legalization 2012; residency requirement removed by emergency rule

California

California has never implemented residency requirements in either its medical marijuana program (operational since 1996) or adult-use program (launched 2018). The state's Medicinal and Adult-Use Cannabis Regulation and Safety Act explicitly permits out-of-state investment and ownership, subject to background checks and financial disclosure requirements. California's approach reflects the state's position as the nation's largest cannabis market, with $5.3 billion in legal sales in 2025, and recognition that residency requirements would face immediate constitutional challenge.

Colorado

Colorado's Amendment 64, approved by voters in 2012, required marijuana business owners to be Colorado residents for at least two years before applying for licenses. The Colorado General Assembly eliminated the residency requirement in 2017 through House Bill 1258, which allowed out-of-state investors to hold up to 100% ownership in Colorado cannabis businesses. The change followed legal analysis concluding that the residency mandate would not survive dormant Commerce Clause challenge. Colorado's market has since seen significant MSO investment, with Curaleaf, Trulieve, and Columbia Care acquiring Colorado operators.

Illinois

Illinois included residency requirements in its 2013 medical marijuana program but omitted them from the Cannabis Regulation and Tax Act, which legalized adult-use cannabis in 2019. The adult-use law instead prioritized social equity through a point system that awarded advantages to Illinois residents from communities disproportionately impacted by cannabis prohibition, without mandating residency. This approach survived legal scrutiny by providing preferences rather than absolute barriers. Illinois collected $1.4 billion in adult-use cannabis tax revenue between 2020 and 2025.

Maine

Maine's residency requirement litigation established controlling precedent for the First Circuit. The state initially required that investors holding more than 10% of a cannabis business be Maine residents for at least four years, later reduced to one year. In Brierley v. Frey, the district court found that Maine's justifications—preventing diversion to other states, ensuring compliance with state law, and promoting economic development—did not satisfy strict scrutiny. The First Circuit affirmed, holding that residency requirements constitute facial discrimination against interstate commerce. Maine's adult-use market launched in 2020 without residency restrictions, and the state issued over 1,200 licenses by 2025.

Michigan

Michigan voters approved adult-use legalization in 2018 with a two-year residency requirement for license applicants. The Michigan Marijuana Regulatory Agency eliminated the requirement in 2020 after the state attorney general issued an opinion concluding that the mandate violated the dormant Commerce Clause and could not be defended in court. The change accelerated MSO entry into Michigan's market. By 2025, Michigan had issued over 1,800 licenses and generated $3.2 billion in cumulative adult-use sales. Critics argue that eliminating residency requirements enabled corporate consolidation at the expense of local operators.

Montana

Montana legalized adult-use cannabis in 2020 with a one-year residency requirement for license applicants. As of June 2026, Montana's residency requirement remains in statute but faces active legal challenge. Out-of-state investors filed suit in federal district court in 2025, arguing that the requirement violates the dormant Commerce Clause. Legal observers expect Montana to settle or lose the case based on established precedent. Montana's adult-use market launched in 2022 and generated $250 million in sales in 2025.

New York

New York legalized adult-use cannabis in 2021 through the Marijuana Regulation and Taxation Act without residency requirements for license applicants. The state instead prioritized social equity through the Conditional Adult-Use Retail Dispensary program, which reserved the first 150 retail licenses for individuals with prior cannabis convictions or their family members. New York's approach reflects lessons learned from other states' failed residency mandates. The state's adult-use market launched in December 2022, and regulators had issued over 400 licenses by mid-2026.

Oklahoma

Oklahoma voters approved medical marijuana in 2018 with a two-year residency requirement for license applicants. In Neder v. Oklahoma, the U.S. District Court for the Western District of Oklahoma struck down the residency requirement in 2021, finding that Oklahoma's stated justifications were pretextual and the law discriminated against interstate commerce. The Tenth Circuit affirmed in 2022. Oklahoma's medical marijuana program became one of the nation's most permissive, issuing over 9,000 cultivation licenses and 2,000 dispensary licenses by 2025. The elimination of residency requirements contributed to rapid market saturation and wholesale price collapse, with wholesale flower prices falling from $2,500 per pound in 2019 to under $500 per pound in 2024.

Market and Business Implications

The elimination of residency requirements has fundamentally reshaped cannabis market structure, accelerating consolidation among multi-state operators while reducing barriers to entry for well-capitalized investors.

MSO Expansion and Market Concentration

Multi-state operators have aggressively expanded into markets where residency requirements have fallen. Curaleaf operates 151 dispensaries across 18 states as of 2026, with significant presence in Florida, New Jersey, Pennsylvania, and Arizona. The company's market capitalization reached $4.2 billion in mid-2026. Trulieve operates 191 dispensaries, primarily in Florida, and generated $1.2 billion in revenue in 2025. The top five MSOs—Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings—collectively control approximately 15% of the U.S. cannabis market by revenue. This concentration has increased since 2020, when the top five controlled approximately 8%. The elimination of residency requirements has enabled these companies to acquire local operators, consolidate cultivation and processing facilities, and achieve economies of scale in purchasing, compliance, and marketing.

Capital Access and Valuation

Removing residency requirements has improved capital access for cannabis operators by expanding the investor base. Cannabis companies raised $4.8 billion in capital in 2025, up from $3.2 billion in 2020, with institutional investors including hedge funds, private equity firms, and family offices increasing allocations to the sector. Public cannabis companies trade on the Canadian Securities Exchange and over-the-counter markets in the United States, with combined market capitalization exceeding $25 billion as of mid-2026. Residency requirements had previously limited institutional investment by creating jurisdictional risk—investors feared that state laws could change to prohibit out-of-state ownership, stranding capital.

Wholesale Pricing and Supply Dynamics

The entry of well-capitalized MSOs into previously restricted markets has increased cultivation capacity and driven down wholesale prices. In Michigan, wholesale flower prices fell from $3,000 per pound in 2020 to $1,200 per pound in 2025 as MSOs built large-scale cultivation facilities. Similar price compression occurred in Oklahoma, Massachusetts, and Colorado. Lower wholesale prices benefit consumers through reduced retail prices but squeeze margins for small cultivators. Craft growers argue that MSO competition, enabled by the elimination of residency requirements, threatens their viability. Industry data shows that the number of active cultivation licenses has declined in mature markets as small operators exit due to unprofitability.

Social Equity Outcomes

The impact of eliminating residency requirements on social equity remains contested. Proponents argue that residency mandates did not effectively promote equity because they failed to distinguish between wealthy in-state investors and economically disadvantaged residents. Data from Illinois shows that social equity applicants won 21% of adult-use licenses in the first application round, despite the absence of residency requirements, by using targeted scoring criteria and technical assistance programs. Critics counter that MSO dominance, accelerated by the elimination of residency requirements, has marginalized minority-owned businesses. A 2024 study by the Minority Cannabis Business Association found that Black and Latino entrepreneurs own less than 2% of cannabis dispensaries nationally, despite representing 30% of the U.S. population. The study attributed this disparity partly to capital access barriers that residency requirements did not address but that MSO expansion has exacerbated.

Interstate Commerce and Federal Reform

The elimination of state residency requirements sets the stage for interstate cannabis commerce if federal prohibition ends. The Cannabis Administration and Opportunity Act, introduced in the U.S. Senate in 2021 and reintroduced in modified form in 2023, would deschedule cannabis and permit interstate commerce subject to federal regulation. With residency requirements already eliminated in most states, MSOs are positioned to operate national supply chains, distributing products from low-cost cultivation states like Oklahoma and Michigan to high-price markets like New York and New Jersey. Federal legalization would likely trigger further consolidation, with the largest MSOs acquiring regional operators to build national brands. Industry analysts project that the top 10 companies could control 40-50% of a federally legal market, similar to concentration levels in the alcohol and tobacco industries.

What Experts Say About Residency Requirements

Legal scholars, industry analysts, and policy advocates have reached broad consensus that cannabis residency requirements are constitutionally indefensible, though they disagree on the policy implications. Professor Sam Kamin of the University of Denver has stated that residency requirements represent "well-intentioned but legally flawed attempts to keep cannabis local," noting that the dormant Commerce Clause does not permit states to discriminate against interstate commerce even for legitimate policy goals. According to Kamin, states can achieve local control objectives through nondiscriminatory means such as local licensing authority, zoning restrictions, and community benefit agreements. Professor Robert Mikos of Vanderbilt Law School has written that the federal illegality of cannabis does not